The Collaborative Research Initiative will be a strategic expansion of the company’s ‘Project Boveri: Find the Cure,’ adding the ability to monitor hourly chromosome aneuploidy progression. ChromoCure’s technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication.
ChromoCure believes that its cancer detection and progression measurement capabilities provide unprecedented monitoring and objective measurement of therapeutic research and results.
ChromoCure’s focus on cancer research has been validated and further underscored by recent major clinical publications that both validate company’s chromosomal (aneuploidy) theory of cancer and establish the company’s detection approach as the forefront of both cancer detection and research.
ChromoCure’s technology has proven accurate in the measurement of the unique genomic characteristic found in 100% of all cancers and to have an effective accuracy of 100% for all cancers at all stages.
ChromoCure’s scanner technologies include designs, processes, and algorithms centered on chromosomal imbalance. They provide the foundation for advantages in delivering important results in diagnosis, therapy and cure. The company expects to soon announce important additions and changes to its operations and research in the areas of therapeutics and disease eradication.
ChromoCure develops and provides cancer detection systems and related therapeutic technologies. The company’s CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the genomic characteristic found in 100% of all cancers and never found in normal cells. Its detection technology has an effective accuracy of 100% for all cancers at all stages.